Comparative Pharmacology
Head-to-head clinical analysis: ACLOVATE versus COR OTICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACLOVATE versus COR OTICIN.
ACLOVATE vs COR-OTICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
1-2 drops in each affected ear twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Renal (60-80% unchanged), fecal/biliary (5-10%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic